Jeffrey Bolton Buys 4,000 Shares of Enhabit, Inc. (NYSE:EHAB) Stock

Enhabit, Inc. (NYSE:EHAB) Director Jeffrey Bolton purchased 4,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, with a total value of $34,760.00. Following the completion of the purchase, the director now owns 98,144 shares in the company, valued at $852,871.36. The trade was a 4.25 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Enhabit Stock Performance

Shares of EHAB opened at $8.52 on Friday. The firm has a market cap of $428.39 million, a P/E ratio of -3.67 and a beta of 1.89. Enhabit, Inc. has a twelve month low of $6.85 and a twelve month high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The firm’s 50 day moving average price is $7.56 and its two-hundred day moving average price is $8.31.

Enhabit (NYSE:EHAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The company had revenue of $253.60 million for the quarter, compared to analyst estimates of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same quarter in the previous year, the business earned $0.03 earnings per share. On average, analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. SummerHaven Investment Management LLC lifted its stake in Enhabit by 2.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock valued at $549,000 after acquiring an additional 1,660 shares in the last quarter. FMR LLC raised its holdings in shares of Enhabit by 138.4% in the third quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after purchasing an additional 1,967 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Enhabit by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock worth $443,000 after purchasing an additional 2,078 shares in the last quarter. Quarry LP boosted its holdings in Enhabit by 242.2% during the second quarter. Quarry LP now owns 3,703 shares of the company’s stock worth $33,000 after purchasing an additional 2,621 shares during the last quarter. Finally, Gladius Capital Management LP grew its position in Enhabit by 78.2% in the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock valued at $49,000 after purchasing an additional 2,747 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on EHAB. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 target price (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and upped their price objective for the company from $8.25 to $9.50 in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Enhabit presently has an average rating of “Hold” and a consensus target price of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.